These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35643632)

  • 1. CHEK2 variants: linking functional impact to cancer risk.
    Boonen RACM; Vreeswijk MPG; van Attikum H
    Trends Cancer; 2022 Sep; 8(9):759-770. PubMed ID: 35643632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk.
    Boonen RACM; Wiegant WW; Celosse N; Vroling B; Heijl S; Kote-Jarai Z; Mijuskovic M; Cristea S; Solleveld-Westerink N; van Wezel T; Beerenwinkel N; Eeles R; Devilee P; Vreeswijk MPG; Marra G; van Attikum H
    Cancer Res; 2022 Feb; 82(4):615-631. PubMed ID: 34903604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk.
    Stolarova L; Kleiblova P; Zemankova P; Stastna B; Janatova M; Soukupova J; Achatz MI; Ambrosone C; Apostolou P; Arun BK; Auer P; Barnard M; Bertelsen B; ; Blok MJ; Boddicker N; Brunet J; Burnside ES; Calvello M; Campbell I; Chan SH; Chen F; Chiang JB; Coppa A; Cortesi L; Crujeiras-González A; ; De Leeneer K; De Putter R; DePersia A; Devereux L; Domchek S; Efremidis A; Engel C; Ernst C; Evans DGR; Feliubadaló L; Fostira F; Fuentes-Ríos O; Gómez-García EB; González S; Haiman C; Hansen TVO; Hauke J; Hodge J; Hu C; Huang H; Ishak NDB; Iwasaki Y; Konstantopoulou I; Kraft P; Lacey J; Lázaro C; Li N; Lim WK; Lindstrom S; Lori A; Martinez E; Martins A; Matsuda K; Matullo G; McInerny S; Michailidou K; Montagna M; Monteiro ANA; Mori L; Nathanson K; Neuhausen SL; Nevanlinna H; Olson JE; Palmer J; Pasini B; Patel A; Piane M; Poppe B; Radice P; Renieri A; Resta N; Richardson ME; Rosseel T; Ruddy KJ; Santamariña M; Dos Santos ES; Teras L; Toland AE; Trentham-Dietz A; Vachon CM; Volk AE; Weber-Lassalle N; Weitzel JN; Wiesmuller L; Winham S; Yadav S; Yannoukakos D; Yao S; Zampiga V; Zethoven M; Zhang ZW; Zima T; Spurdle AB; Vega A; Rossing M; Del Valle J; De Nicolo A; Hahnen E; Claes KBM; Ngeow J; Momozawa Y; James PA; Couch FJ; Macurek L; Kleibl Z
    Clin Cancer Res; 2023 Aug; 29(16):3037-3050. PubMed ID: 37449874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
    Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
    Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.
    Kleiblova P; Stolarova L; Krizova K; Lhota F; Hojny J; Zemankova P; Havranek O; Vocka M; Cerna M; Lhotova K; Borecka M; Janatova M; Soukupova J; Sevcik J; Zimovjanova M; Kotlas J; Panczak A; Vesela K; Cervenkova J; Schneiderova M; Burocziova M; Burdova K; Stranecky V; Foretova L; Machackova E; Tavandzis S; Kmoch S; Macurek L; Kleibl Z
    Int J Cancer; 2019 Oct; 145(7):1782-1797. PubMed ID: 31050813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast and colorectal cancer risks among over 6,000 CHEK2 pathogenic variant carriers: A comparison of missense versus truncating variants.
    Mundt E; Mabey B; Rainville I; Ricker C; Singh N; Gardiner A; Manley S; Slavin T
    Cancer Genet; 2023 Nov; 278-279():84-90. PubMed ID: 37839337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study.
    Le Calvez-Kelm F; Lesueur F; Damiola F; Vallée M; Voegele C; Babikyan D; Durand G; Forey N; McKay-Chopin S; Robinot N; Nguyen-Dumont T; Thomas A; Byrnes GB; ; Hopper JL; Southey MC; Andrulis IL; John EM; Tavtigian SV
    Breast Cancer Res; 2011 Jan; 13(1):R6. PubMed ID: 21244692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rare, protein-truncating variants in
    Decker B; Allen J; Luccarini C; Pooley KA; Shah M; Bolla MK; Wang Q; Ahmed S; Baynes C; Conroy DM; Brown J; Luben R; Ostrander EA; Pharoah PD; Dunning AM; Easton DF
    J Med Genet; 2017 Nov; 54(11):732-741. PubMed ID: 28779002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the role of CHEK2 p.(Asp438Tyr) allele in inherited breast cancer predisposition.
    Kumpula TA; Koivuluoma S; Soikkonen L; Vorimo S; Moilanen J; Winqvist R; Mantere T; Kuismin O; Pylkäs K
    Fam Cancer; 2023 Jul; 22(3):291-294. PubMed ID: 36653541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Missense mutations (p.H371Y, p.D438Y) in gene CHEK2 are associated with breast cancer risk in women of Balochistan origin.
    Baloch AH; Daud S; Raheem N; Luqman M; Ahmad A; Rehman A; Shuja J; Rasheed S; Ali A; Kakar N; Naseeb HK; Mengal MA; Awan MA; Wasim M; Baloch DM; Ahmad J
    Mol Biol Rep; 2014 Feb; 41(2):1103-7. PubMed ID: 24390236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CHK2 kinase is recurrently mutated and functionally impaired in the germline of pediatric cancer patients.
    Wagener R; Walter C; Auer F; Alzoubi D; Hauer J; Fischer U; Varghese J; Dugas M; Borkhardt A; Brozou T
    Int J Cancer; 2023 Apr; 152(7):1388-1398. PubMed ID: 36468172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system.
    Delimitsou A; Fostira F; Kalfakakou D; Apostolou P; Konstantopoulou I; Kroupis C; Papavassiliou AG; Kleibl Z; Stratikos E; Voutsinas GE; Yannoukakos D
    Hum Mutat; 2019 May; 40(5):631-648. PubMed ID: 30851065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer risks associated with missense variants in breast cancer susceptibility genes.
    Dorling L; Carvalho S; Allen J; Parsons MT; Fortuno C; González-Neira A; Heijl SM; Adank MA; Ahearn TU; Andrulis IL; Auvinen P; Becher H; Beckmann MW; Behrens S; Bermisheva M; Bogdanova NV; Bojesen SE; Bolla MK; Bremer M; Briceno I; Camp NJ; Campbell A; Castelao JE; Chang-Claude J; Chanock SJ; Chenevix-Trench G; ; Collée JM; Czene K; Dennis J; Dörk T; Eriksson M; Evans DG; Fasching PA; Figueroa J; Flyger H; Gabrielson M; Gago-Dominguez M; García-Closas M; Giles GG; Glendon G; Guénel P; Gündert M; Hadjisavvas A; Hahnen E; Hall P; Hamann U; Harkness EF; Hartman M; Hogervorst FBL; Hollestelle A; Hoppe R; Howell A; ; ; Jakubowska A; Jung A; Khusnutdinova E; Kim SW; Ko YD; Kristensen VN; Lakeman IMM; Li J; Lindblom A; Loizidou MA; Lophatananon A; Lubiński J; Luccarini C; Madsen MJ; Mannermaa A; Manoochehri M; Margolin S; Mavroudis D; Milne RL; Mohd Taib NA; Muir K; Nevanlinna H; Newman WG; Oosterwijk JC; Park SK; Peterlongo P; Radice P; Saloustros E; Sawyer EJ; Schmutzler RK; Shah M; Sim X; Southey MC; Surowy H; Suvanto M; Tomlinson I; Torres D; Truong T; van Asperen CJ; Waltes R; Wang Q; Yang XR; Pharoah PDP; Schmidt MK; Benitez J; Vroling B; Dunning AM; Teo SH; Kvist A; de la Hoya M; Devilee P; Spurdle AB; Vreeswijk MPG; Easton DF
    Genome Med; 2022 May; 14(1):51. PubMed ID: 35585550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
    Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
    Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
    Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low prevalence of CHEK2 gene mutations in multiethnic cohorts of breast cancer patients in Malaysia.
    Mohamad S; Isa NM; Muhammad R; Emran NA; Kitan NM; Kang P; Kang IN; Taib NA; Teo SH; Akmal SN
    PLoS One; 2015; 10(1):e0117104. PubMed ID: 25629968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma.
    Havranek O; Kleiblova P; Hojny J; Lhota F; Soucek P; Trneny M; Kleibl Z
    PLoS One; 2015; 10(10):e0140819. PubMed ID: 26506619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline variants in cancer genes in high-risk non-BRCA patients from Puerto Rico.
    Dutil J; Teer JK; Golubeva V; Yoder S; Tong WL; Arroyo N; Karam R; Echenique M; Matta JL; Monteiro AN
    Sci Rep; 2019 Nov; 9(1):17769. PubMed ID: 31780696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.